EUVIMEDEUVIMED entdecken
Leitlinie

Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline

S Susan Hedayati iD, Jodie L Babitt, Jeffrey S Berns, Biykem Bozkurt, Rebecca S Cheung, Yarieli Cuevas iD, Emmanuel E Effa, Michele F Eisenga iD, Steven Fishbane, Yelena Z Ginzburg iD, Volker H Haase iD, Siah Kim und 14 weitere

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-26-02326 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von S Susan Hedayati und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Stony Brook University School of Medicine, Stony Brook, New York, and Division of Nephrology, University of Texas Southwester…. Hauptthemen laut MEDLINE: Anemia, Renal Insufficiency, Chronic. Die Arbeit nennt 104 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) provides an update of the 2012 version. Its scope includes anemia diagnosis and use of iron therapy, erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs), and red blood cell (RBC) transfusions to treat anemia in CKD. METHODS: An international work group of patient partners, health care professionals, researchers, and clinicians defined the guideline scope. An independent evidence review team conducted systematic reviews through October 2024 and graded the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. The final guideline incorporated feedback from a public review involving registered stakeholders in late 2024. RECOMMENDATIONS: This synopsis focuses on the 8 graded recommendations. Key points include the use of transferrin saturation and ferritin thresholds to guide iron therapy, with intravenous iron preferred over oral iron in people receiving hemodialysis; addressing correctable causes of anemia before use of an ESA or a HIF-PHI; using an ESA rather than a HIF-PHI as first-line treatment; individualized hemoglobin (Hb) thresholds for ESA initiation based on patient characteristics, symptoms, and values; and an upper Hb target of below 11.5 g/dL (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaRenal Insufficiency, ChronicHumansHematinicsIronErythrocyte TransfusionRenal DialysisProlyl-Hydroxylase InhibitorsFerritinsHypoxia-Inducible Factor-Proline Dioxygenases

Substanzen

HematinicsIronProlyl-Hydroxylase InhibitorsFerritinsHypoxia-Inducible Factor-Proline Dioxygenases

Autor:innen und Institutionen

  • Division of Nephrology, Stony Brook University School of Medicine, Stony Brook, New York, and Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas (S.S.H.).
  • Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts (J.L.B.).
  • Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.B.).
  • Winters Center for Heart Failure, Cardiology, Baylor College of Medicine, Houston, Texas (B.B.).
  • Corporate and Foundation Relations, University of Washington Medicine, Seattle, Washington (R.S.C.).
  • Kidney Research Institute, Lexington, Kentucky (Y.C.).

ORCID-Profile: S Susan Hedayati, Yarieli Cuevas, Michele F Eisenga, Yelena Z Ginzburg, Volker H Haase, Manisha Sahay, Angela Yee-Moon Wang, David C Wheeler, Karen A Robinson, Lisa M Wilson, Amy Earley, Marcello Tonelli, Evi V Nagler

Zitieren

APA

Hedayati, S. S., Babitt, J. L., Berns, J. S., Bozkurt, B., Cheung, R. S., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., Kim, S., Moura-Neto, J. A., Rossignol, P., Sahay, M., Tanaka, T., Wang, A. Y., Wheeler, D. C., Robinson, K. A., …, & Nagler, E. V. (2026). Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. Annals of Internal Medicine. https://doi.org/10.7326/annals-26-02326

Vancouver

Hedayati SS, Babitt JL, Berns JS, Bozkurt B, Cheung RS, Cuevas Y, et al. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. Annals of Internal Medicine. 2026. doi:10.7326/annals-26-02326

BibTeX
@article{Hedayati2026,
  author = {Hedayati, S Susan and Babitt, Jodie L and Berns, Jeffrey S and Bozkurt, Biykem and Cheung, Rebecca S and Cuevas, Yarieli and Effa, Emmanuel E and Eisenga, Michele F and Fishbane, Steven and Ginzburg, Yelena Z and Haase, Volker H and Kim, Siah and Moura-Neto, Jose A and Rossignol, Patrick and Sahay, Manisha and Tanaka, Tetsuhiro and Wang, Angela Yee-Moon and Wheeler, David C and Robinson, Karen A and Wilson, Lisa M and Wilson, Renée F and King, Jennifer M and Earley, Amy and Akl, Elie A and Tonelli, Marcello and Nagler, Evi V},
  title = {Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-26-02326}
}
Kostenlos starten →